In summary, mRNA expression in tissue or immunohistochemistry staining of NOTCH3 from primary tumor tissue are likely to be stable predictive methods for prognosis and response to chemotherapy in patients with advanced NSCLC. This evidence concerns the gene NOTCH3 and neoplasm.